BioDelivery Sciences International, Inc.
News and overview for BioDelivery Sciences International, Inc.
BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain
News-Medical.Net | 46 days 17 hours 9 minutes ago
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that its commercial partner Meda will launch the FDA-approved ONSOLIS (fentanyl buccal soluble film) next week for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Meda Launches Onsolis(TM) (Fentanyl Buccal Soluble Film) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients [Press Release]
PRNewswire | 41 days 13 hours 39 minutes ago
SOMERSET, N.J., Oct. 13 /PRNewswire/ -- Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)( )(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Onsolis uses an innovative drug delivery technology called BioErodible MucoAdhesive (BEMA(TM)), developed by BioDelivery Sciences...
Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain
News-Medical.Net | 41 days 17 hours 12 minutes ago
Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)( )(fentanyl buccal soluble film) in the U
3 Results
Sign up for SNM SmartBrief
Company Overview
| Company: | BioDelivery Sciences International, Inc. |
|---|---|
| Industry: | Drug Delivery Systems |
| Website: | http://www.bdsinternational.com |
BioDelivery Sciences International isn't inventing new drugs, but it is looking for better ways to administer them. The development-stage firm takes already approved drugs that are normally delivered intravenously and reformulates them into buccal (absorbed by the inner cheek) and oral treatments. Drugs delivered via its BEMA and Bioral systems are being studied to treat acute pain and fungal infections, respectively. BioDelivery Sciences is awaiting FDA approval of its BEMA Fentanyl candidate, which consists of a dissolving disc that delivers the cancer pain drug buccally. Swedish partner Meda AB has commercial rights to this product in the US, Canada, Europe, and Mexico.
Key Numbers
| Sales in U.S. Dollars (mil.) | 0.3 (2008) |
|---|---|
| One-year % Growth in Sales | 30.3 (2008) |
| Net Income in U.S. Dollars (mil.) | -17.2 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 22 (2008) |
| One-year % Growth in Number of Employees | 0.0 (2008) |
| Fiscal Year-End | December |